General Topics
More than 200 body parts from Gunther von Hagens' laboratory in Germany will be used to teach anatomy to medical students at the University of Warwick. This is the first time Von Hagens' plastinated specimens have been used for teaching by a UK medical school.
Boston Scientific Corporation (NYSE: BSX) announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System. The TAXUS Express Atom Stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels. It is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter. No other DES for sale in the U.S.
ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services, announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for commercialization of the ATS 3f(R) Aortic Bioprosthesis. The Company looks forward to offering this unique tissue valve as the standard of care for the Australian market.
New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
(613) 686-5745 Cerepotec Pharmalef
180 Medical, one of America's fastest growing "Nationally Accredited" providers of sterile use catheters, urologic and disposable medical supplies, announced today their one-of-a-kind catheter DVD is now available in Spanish, making catheter information accessible to even more people in need.
Home Diagnostics, Inc. (NASDAQ:HDIX), a leading manufacturer and marketer of diabetes testing supplies, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration for the world's smallest blood glucose meter, TRUE2goT, and for TRUEresultT, the company's latest advanced performance, no-coding meter for at-home testing.
Olympus America Inc. formally introduced its advanced technology platform that now allows surgeons to perform minimally invasive single-site surgery through the umbilicus (belly button), which may result in less abdominal trauma, less post-operative pain, less internal/external scarring and improved recovery for patients.
Esploron www.esploron.com integrates business, science and industry expertise to develop innovative solutions that work! Although biotechnology and pharmaceutical companies are spending more on research and development, commercially viable innovations are decreasing.
(613) 686-5745 Cerepotec Pharmalef
The first family-based genome-wide association study in Alzheimer's disease has identified the sites of four novel genes that may significantly influence risk for the most common late-onset form of the devastating neurological disorder.
The University of Pittsburgh Cancer Institute (UPCI) will be the primary site for a clinical trial of ABT-888 a drug previously proven in combination treatments to improve chemotherapy's effectiveness by lowering cancer cells' resistance to treatment. This trial will, for the first time, examine ABT-888 as a single agent for patients with cancers related to BRCA 1 or 2 genetic mutations, which predispose patients to breast and ovarian cancers.
The three finalists of the 2008 EUROPEAN BIOTECHNICA AWARD have been determined. The biotechnology companies nominated are Cambridge-based Astex Therapeutics Limited (UK), GENEART AG from Regensburg (Germany) and immatics biotechnologies GmbH based in Tübingen (Germany). The prize, worth EUR 100,000, is awarded to innovative European biotechnology and life sciences companies.
Clinproxy’s, www.clinproxy.com global spread continues to acknowledge to issues with regards to developing countries and the compliance required for clinical trials.
(613) 686-5745 Cerepotec Pharmalef
Highlights of April's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include the first international, peer-reviewed report on LASIK patient satisfaction, data on increased cataract risk in patients who use combined steroids, and the first large study of refractive error and vision correction in American preschool children.
Research results highlighting three new devices used to reduce blockages in peripheral and coronary arteries and to provide cardiac support will be presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).
St. Jude Medical, Inc. (NYSE:STJ) today announced Australian Therapeutic Goods Administration (TGA) approval of the Eon MiniT neurostimulator, the world's smallest, longest-lasting rechargeable device in its class to treat chronic pain of the trunk or limbs and pain from failed back surgery. In Australia, the Eon Mini neurostimulator is reimbursable via the private health system.
Limdato, www.limdato.com knows that you will never see effective monitoring results unless you know the “red flag” issues in your trial.
(613) 686-5745 Cerepotec Pharmalef
An attorney for the state of Alabama on Monday asked a jury to order Germany-based generic drug manufacturer Sandoz to pay as much as $170 million for allegedly overcharging the state's Medicaid program for prescription drugs for more than 10 years, the Miami Herald reports. Sandoz, a subsidiary of
Now that the popularity of hormone replacement therapy (HRT) has declined, so too has the number of myocardial infarctions, or heart attacks, in menopausal women each year, a new study has found. There has been no such difference in the rate of strokes, however. The study, which appears in the May issue of the journal Medical Care, looked at whether the decreased use of HRT has affected the rate of cardiovascular health outcomes.
Clinical trial results presented today at the American Diabetes Association annual meeting show that overall rates of cardiovascular hospitalization and cardiovascular death are similar in patients taking Avandia (rosiglitazone) compared to those receiving metformin and sulfonylurea.
Pharmalef Developments www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party
(613) 686-5745 Cerepotec Pharmalef
Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated
www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.
One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.
Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.
This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.
Cereprotec Inc.
www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.
At this moment Cereprotec Inc.
www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.
In Phase II Cereprotec Inc.
www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated
www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.
This company is also developing a family of other promising novel chemical compounds.
Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.
Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation")
www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc.
www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.
Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.
Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.
Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments .
www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.
In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
Pharmalef Developments
www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments
www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.
They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.
They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008
A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/200802278381. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.
3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.
4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.
5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.
6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.
7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.
8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.
9. The method according to claim 8, wherein said head trauma injury is closed head injury.
10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.
11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.
12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.
13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.
14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.
15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.
16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.
17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.
18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.
19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.
20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.
21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
Medical Training
A new teaching aid, the FRAX Slide-kit, has been launched by the International Osteoporosis Foundation (IOF) in cooperation with the World Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK. The educational slides can be downloaded free of charge from the
Chief Medical Officer for England (CMO) Sir Liam Donaldson has laid out plans which will require that doctors renew their professional registration every five years. Sir Liam said they are aimed at improving patient safety and supporting professionals in sustaining their high standards. The proposals are outlined in the report
"Science has the potential to help solve some of the great problems facing us and to help drive the economy out of recession. At a time of great economic uncertainty it is reassuring that the Prime minister is maintaining his long held commitment to science. Maintaining current investment is a good place to start but we must also look to see where we can put more money in to capitalise on our world leading science in areas such as energy.
The key benefit of having a full service CRO is their ability to asses and expand risk management and to encompass a broader range of risk issues.
(613) 686-5745 Cerepotec Pharmalef
The American Psychological Association urged psychologists today to take a leading role in ending discrimination based on gender identity, calling upon the profession to provide "appropriate, nondiscriminatory treatment to all transgender and gender-variant individuals" and encouraging more research into all aspects of gender identity and expression.
Boston Medical Center has received a one-year grant for $50,000 from The Avon Foundation to support the Child Witness to Violence Project (CWVP) a counseling, advocacy and outreach program that focuses on young children who are bystanders to community and domestic violence. CWVP will use the grant to create a partnership to train police officers to better recognize and respond to children affected by violence.
"Examining Sources of Coverage Among Medicare Beneficiaries: Supplemental Insurance, Medicare Advantage, and Prescription Drug Coverage -- Findings From the Medicare Current Beneficiary Survey," Kaiser Family Foundation: The chartpack provides new information on the sources of supplemental and prescription drug coverage among Medicare beneficiaries in 2006.
With a focus on familiar, everyday health problems, Pharmalef Developments . www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.
(613) 686-5745 Cerepotec Pharmalef
The Royal Australian College of General Practitioners (RACGP) has released the GP Pathway program, a series of online learning activities that provide an overview of the training process for Australian general practice. The first module of the GP Pathway program Setting the scene - an introduction to becoming a GP in the Australian health system is specifically designed for medical students and medical graduates who are interested in a career in general practice.
The National Association of Biology Teachers (NABT) will recognize Dr. Randy Moore, a professor of biology at the University of Minnesota, with the 2008 Evolution Education Award during the NABT annual conference to be held 15-18 October 2008 in Memphis, Tennessee. The Evolution Education Award is cosponsored by the American Institute of Biological Sciences (AIBS) and the Biological Sciences Curriculum Study (BSCS).
Nursing faculty at UNLV and Nevada State College (NSC) are collaborating to improve nurse retention and patient care in Nevada by expanding opportunities for registered nurses (RN) to earn a bachelor of science in nursing (BSN) through an online degree program. This is the first coordinated effort of its kind in Nevada and is being funded by a grant from the Health Resource and Services Administration (HRSA).
Kriger Research Group International www.krigerclinical.com provides clinical research services for pharmaceutical and biotechnology product development from phase II through phase IV for US, Canadian, European and multinational pharmaceutical companies. KRGI is your way to high quality design, conduct and analysis of clinical trials.
(613) 686-5745 Cerepotec Pharmalef
Administrators, faculty and staff are making considerable progress toward the opening of the Oakland University William Beaumont School of Medicine, which plans to begin accepting student applications in 2010 pending accreditation by the Liaison Committee for Medical Education.
The National Association of Biology Teachers (NABT) will recognize Dr. Randy Moore, a professor of biology at the University of Minnesota, with the 2008 Evolution Education Award during the NABT annual conference to be held 15-18 October 2008 in Memphis, Tennessee. The Evolution Education Award is cosponsored by the American Institute of Biological Sciences (AIBS) and the Biological Sciences Curriculum Study (BSCS).
AcademyHealth and the Robert Wood Johnson Foundation have awarded ten scholarships to graduate students who demonstrate outstanding potential to contribute to the field of public health systems research (PHSR). Scholarship recipients each receive $1,000 for registration and travel to attend AcademyHealth's Annual Research Meeting and the PHSR Interest Group Annual Meeting, June 28-July 1, 2009 in Chicago.
Clinproxy is a Contract Research Organization www.clinproxy.com that is attempting to change the idea that has overwhelmed the Biopharmaceutical Industry, that for a company to survive it had to exist in competition with all others.
(613) 686-5745 Cerepotec Pharmalef
The Royal College of Physicians and Surgeons of Canada commends The Honourable Stephen Goudge and the Commission of the Inquiry into Pediatric Forensic Pathology in Ontario for a comprehensive and thoughtful report. Among its many recommendations is the identified need for high standards in the medical education of forensic pathologists.
Mobile Doctors announces a new date for its 'Excellence in Report Writing' training in response to demand from GPs and specialists. Mobile Doctors, one of the UK's leading providers of medical evidence, is pleased to announce an additional date for its 'Excellence in Report Writing' courses, which provide training on how to compile medico-legal reports and give evidence in court to General Practitioners (GPs) and specialists.
Welch Allyn, a leading manufacturer of frontline medical products and solutions, introduced Diagnosis 101, an online educational resource for medical school students just starting out on their quest to become physicians. The company's microsite, http://www.welchallyn.
Professor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage...
(613) 686-5745 Cerepotec Pharmalef
Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated
www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.
One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.
Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.
This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.
Cereprotec Inc.
www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.
At this moment Cereprotec Inc.
www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.
In Phase II Cereprotec Inc.
www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated
www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.
This company is also developing a family of other promising novel chemical compounds.
Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.
Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation")
www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc.
www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.
Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.
Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.
Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments .
www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.
In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
Pharmalef Developments
www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments
www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.
They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.
They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008
A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/200802278381. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.
3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.
4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.
5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.
6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.
7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.
8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.
9. The method according to claim 8, wherein said head trauma injury is closed head injury.
10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.
11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.
12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.
13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.
14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.
15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.
16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.
17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.
18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.
19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.
20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.
21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.
Medical Devices
Using new technologies that make it easier to sequence the human genome, researchers at the University of Michigan Comprehensive Cancer Center have identified a series of genes that become fused when their chromosomes trade places with each other. These recurrent gene fusions are thought to be the driving mechanism that causes certain cancers to develop.
Medtronic, Inc. (NYSE: MDT) today announced the commercial availability of its Reveal XTT Insertable Cardiac Monitor (ICM) in the United States, along with the nation's first implant of the new device. The procedure was conducted by Blair Grubb, M.D., professor of Medicine and Pediatrics at the University of Toledo Medical Center, a renowned heart specialist.
A snake is probably the last thing you'd ever want crawling around your heart. But in the case of a new American-Israeli invention called the CardioARM, this medical "snake" device may one day save your life. The new Israeli-American invention came by way of some brainstorming between Israel's Dr. Alon Wolf and his American colleague Prof. Howie Choset, when Wolf was working as a researcher at Carnegie Mellon University in the US.
According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks...
(613) 686-5745 Cerepotec Pharmalef
As the EU begins an investigation into the feasibility of banning mercury in professional-use sphygmomanometers, supporters of a ban have received a boost from a new report detailing the wide use of mercury-free alternatives in the United States.
Adding to its line up of complete total digital imaging and workflow management solutions for eyecare professionals, Canon U.S.A., Inc., a leader in medical imaging, today introduced the CR-1 Mark II Digital Non-Mydriatic Retinal Camera. The CR-1 Mark II can achieve extremely detailed, high-resolution diagnostic images of the retina and enables a full 45-degree view angle to help the eyecare professional detect and monitor ocular conditions.
AdvanDx announced that it has launched a fast, 90 minutes protocol for all CE-IVD marked PNA FISH(R) tests in Europe. The fast protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization time from 90 minutes to 30 minutes.
Clinproxy is a Contract Research Organization www.clinproxy.com that is attempting to change the idea that has overwhelmed the Biopharmaceutical Industry, that for a company to survive it had to exist in competition with all others.
(613) 686-5745 Cerepotec Pharmalef
Siemens will be presenting its latest product advancements at the British Nuclear Medicine Society's Annual Meeting from the 27 - 29 April 2009 at the Manchester Central Convention Complex. This includes information on its innovation, the BiographT mCT for molecular Computed Tomography as well as the Symbia T16 TruePoint SPECT.CT and the world's first intelligent SPECT technology, IQ.SPECT.
The first family-based genome-wide association study in Alzheimer's disease has identified the sites of four novel genes that may significantly influence risk for the most common late-onset form of the devastating neurological disorder.
Medtronic and the Scoliosis Research Society launched Spine Check - a new program designed to help promote scoliosis screenings for middle school and junior high school students. The Scoliosis Research Society (SRS), one of the world's premier spine societies, and Medtronic are supporting the Spine Check program to help improve the overall spinal health of students.
Typically, large CROs compete on the basis of medical and scientific expertise in specific therapeutic areas; the ability to manage large-scale trials on a global basis with strategically located facilities
(613) 686-5745 Cerepotec Pharmalef
As the nineteenth Drug Delivery to the Lungs (DDL) conference rapidly approaches, DDL Chairman Sandy Munro offers his views on what he anticipates to be the highlights for this years' conference; including the aim to maintain DDL's unique format, promote its international reach and reveal what's in store for next year's 20th anniversary event.
In a development that researchers say is likely to quell concerns about the value of costly computed tomography (CT) scans to diagnose coronary artery blockages, an international team led by researchers at Johns Hopkins reports solid evidence that the newer, more powerful 64-CT scans can easily and correctly identify people with major blood vessel disease and is nearly as accurate as invasive coronary angiography. Reporting in the New England Journal of Medicine online Nov.
Amedica Corporation, an orthopedic implants company focused on silicon nitride ceramic technologies, announced that it has received a CE (Conformite Europeene) mark for initial rollout of their spinal intervertebral spacers using novel CSC (cancellous-structured ceramic) technology. The CSC technology, made using Amedica's novel silicon nitride ceramic, offers a porous cancellous trabecular structure designed to promote bony fusion.
As per Esploron www.esploron.com executive management the cost of drug development has soared during the past ten years compelling pharmaceutical and biotechnology companies to look for new, smarter ways of conducting clinical research.
(613) 686-5745 Cerepotec Pharmalef
Lehigh University assistant professor of neuroscience Michael Burger has been awarded a $1.8 million grant from the National Institutes of Health's (NIH) National Institute on Deafness and Other Communication Disorders for his research entitled "Efferent Inhibitory Mechanisms in Binaural Processing.
University of Arkansas for Medical Sciences (UAMS) surgeon Rabii Madi, M.D., became the first in the nation to perform a double robotic surgery, removing a patient's cancerous kidney and cancerous prostate through a single, small incision using the da Vinci Surgical System robot.
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. Food and Drug Administration (FDA) approval of its Cool PointT Irrigation Pump. Used in conjunction with SJM open-irrigated ablation catheters, an irrigation pump supplies a continuous flow of saline through the catheter's inner lumen to cool the ablation electrode for more effective energy delivery.
The key benefit of having a full service CRO is their ability to asses and expand risk management and to encompass a broader range of risk issues.
(613) 686-5745 Cerepotec Pharmalef
Cereprotec Inc. and Institute of Applied Chemistry at Hebrew University are working together to synthesise new Glycoluril Derivatives with Possible Neuroprotection Effects.According to report of Institute of Applied Chemistry they have performed the third step as it appears in the synthesis route scheme. This took much longer than the other steps, after all, this reaction doesn't appear in any literature and in the end only took two and half weeks. This research is fully sponsored by Cereprotec Incorporated
www.cereprotec.com a US company that already runs clinical tests of their first drug Cereprotex .
In the reaction between compound II and III, one gets two main products, three additional compounds in small quantities plus unreacted starting materials and one main side product. All together there were 8 compounds in the reaction mixture.
One of the main materials precipitated out from the mixture and was removed via filtration from the reaction mixture. This material was cleaned up via crystallization but turned out not to be the desired compound.
The second main material was separated via silica gel column chromatography. Unfortunately, this main material came off at the same Rf value as another material. They tested out several solvents and found that ethyl acetate was able to crystallize out the main material.
Using NMR and elemental analysis, Institute of Applied Chemistry were able to prove that the crystallized out material is indeed Compound III. Yield was 17%. Two grams of material was obtained, enough to try out Stage IV.
This step can be repeated in the future in order to produce more of compound III.
Cereprotec Inc. Phase II clinical study of efficacy and safety of Cereprotex as preventive treatment of cognitive dysfunction as a complication of coronary artery bypass graft (CABG) surgery.Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB).While overt neurological dysfunction occurs in 3% of patients, cognitive dysfunction is detectable in most patients early after CABG and in up to half of patients at six months.
Cereprotec Inc.
www.cereprotec.com proposes to use Cereprotex prior to and after CABG procedures in order to minimize or eliminate entirely the effects of neuro-impairment. Based on the successful animal trials Cereprotec Inc. believes that the human trials will show significant reduction in neuro-impairment.
At this moment Cereprotec Inc.
www.cereprotec.com is prepared to start clinical trials and is actively seeking serious investors.
Cereprotec Inc: Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cerebral dysfunction is a significant complication of coronary artery bypass graft (CABG) surgery using cardiopulmonary bypass (CPB). Cognitive dysfunction is detectable in up to 70% of patients.
In Phase II Cereprotec Inc.
www.cereprotec.com study patients will undergo a standard battery of 10 cognitive tests performed by one examiner before surgery and at 7 and one month after CABG. Four tests (auditory verbal learning test (AVLT), adult memory and information processing battery (AMIBP), trail-making test B (TMTB), and verbal fluency test (VFT)) will be used to calculate a composite cognitive index.
US Patent Application No.11/723,011 to be assigned to CEREPROTEC INC. Method for Neuroprotection with Glycoluril DerivativesCereprotec Incorporated
www.cereprotec.com is a US company involved in the development of neuroprotective drug Cereprotex.
This company is also developing a family of other promising novel chemical compounds.
Proof of efficacy of these compounds has been obtained in three animal studies including hypoxia in both mice and rats and brain trauma in mice. The proof of neuroprotection concept has been shown not only for prevention (hypoxia model), but also for the treatment paradigm post brain trauma which reflects a potential realistic situation in humans.
Professor Esther Shohami has joined the board of advisors of Cereprotec IncorporatedProfessor Esther Shohami has joined the board of advisors of Cereprotec Incorporated. Her research interests include: Pathophysiology of brain injury - mediators of delayed neuronal damage e.g., prostaglandins, reactive oxygen species, cytokines, cannabinoids, and the cholinergic system in rat and mouse models of injury (closed head injury, CHI). Evaluation of potential therapeutic strategies. CHI as a risk factor for delayed onset of Alzheimer's disease. Genetic manipulations (cytokines or apoE knockouts, acetylcholine-esterase transgenics, and more) as tools for investigating the role of specific mediators in traumatic brain injury. Interrelationship between traumatic brain injury and bone remodeling. Role of endocannabinoids in blood-brain barrier function and in bone remodeling after brain trauma. Mechanisms of neuroprotection induced by pre-conditioning (ischemic or heat acclimation). In vitro model for stretch injury that simulates traumatic conditions in astrocytes.
Dr. Roman Kamburg CEO of Cereprotec and the registered owner of 1125 shares in CEREPROTEC Incorporated (the "Corporation")
www.cereprotec.com a corporation incorporated in and under the laws of the State of Delaware, having its registered office at 108 West 13th Street, Wilmington, Delaware, transfered to Dr. Esther Shohami 40 Shares of Common Stock, for no consideration, to be held by the Transferee, her administrators and assignees, subject to all the terms and conditions on which such shares were held by the Transferor, and Transferee agreed to receive such shares.
Pharmalef Inc. is starting collaboration in development of new oral delivery platformPharmalef Inc.
www.pharmalef.com is starting collaboration in development of new oral delivery platform offers pharmaceutical companies the ability to extend the shelf life and stability of medicinal compounds.
Moreover, oral delivery improves patient compliance, improves treatment, reduces patient inconvenience, and reduces treatment costs.
Our partners have completed proof of concept and development of a proliposomal formulation for the model drug, calcitonin, which is used in the treatment of osteoporosis and thyroid cancer.
Clinical trials are expected to begin at a number of centers across the United States, Canada and European Union.
Pharmalef Developments introduces several new products in Rheumatology, Immunology and Respiratory Diseases.With a focus on familiar, everyday health problems, Pharmalef Developments .
www.pharmalef.com aims to develop and deliver products that meet the individual’s health care needs, developing a wide range of products.
In addition to its established range of highly effective and distinctive products Pharmalef Developments will introduce several new products in new fields, including Rheumatology, Immunology and Respiratory Diseases.
Pharmalef Developments plays a vital role in proper documenting the drug development process.New drugs are the lifeblood of the pharmaceutical industry. Yet strict testing and documentation requirements mean only one in many drug candidates make it to market.
Pharmalef Developments
www.pharmalef.com can play a vital role in documenting the drug development process. By leveraging our expertise in business process management and the latest technologies, we can also help you develop a documentation process for clinical trials that is easy and efficient, while satisfying strict government requirements and regulations.
Pharmalef Developments is a home for team-oriented professionalsPharmalef Developments
www.pharmalef.com is a home for team-oriented professionals and their aim is to be the first choice in the industry for licensing and academic collaborations that bring mutual benefits to each party.
They entered into many collaborations with leading academic centers, CRO-s and biotechnology companies to complement our in-house R&D capabilities.
They are always interested in forming new partnerships covering early-stage research, novel compounds or technologies and implementation of clinical trials.
CEREPROTEC Method for Neuroprotection with Glycoluril Derivatives Patent Application has been Published September 18, 2008
A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS) comprises administering a glycoluril derivative to an individual in need thereof. View document here:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=20080227838.PGNR.&OS=DN/20080227838&RS=DN/200802278381. A method for prevention, inhibition or treatment of neuronal degeneration caused by injury, disease, disorder or condition in the central nervous system (CNS), comprising administering to an individual in need thereof an amount effective to treat said injury, disease, disorder or condition, of a compound of the formula I:whereinR.sub.1, R.sub.2 and R.sub.3, the same or different, each is H or (C.sub.1-C.sub.6) alkyl;R.sub.4 is selected from the group consisting of (C.sub.1-C.sub.6) alkyl, --R.sub.5--COOR, --R.sub.5--OH, --R.sub.5--NH--CO--R and --R.sub.5--CO--NH--(CH.sub.2).sub.n--COOR;R.sub.5 is (C.sub.1-C.sub.6) alkylene;R is H or (C.sub.1-C.sub.3) alkyl;n is an integer of 1 to 6; or an enantiomer thereof or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl and R.sub.4 is (C.sub.1-C.sub.6) alkyl.
3. The method according to claim 2, wherein R.sub.1 to R.sub.4 each is methyl.
4. The method according to claim 1, wherein R.sub.1 to R.sub.3 each is H or (C.sub.1-C.sub.6) alkyl, R.sub.4 is --R.sub.5---COOR, R.sub.5 is (C.sub.1-C.sub.6) alkylene and R is H or (C.sub.1-C.sub.3) alkyl.
5. The method according to claim 1, wherein R.sub.1 and R.sub.3 each is methyl, R.sub.2 is H and R.sub.4 is --(CH.sub.2).sub.3COOH.
6. The method according to claim 1, wherein said injury, disease, disorder or condition is selected from the group consisting of: (i) a neurological injury: (ii) brain damage caused by a cardiovascular event; (iii) a cerebrovascular disorder or disease; (iv) a neurodegenerative disease or disorder; and (v) a dementia.
7. The method according to claim 6, wherein said injury is a neurological traumatic injury selected from the group consisting of head trauma injury and spinal cord injury.
8. The method according to claim 7, wherein said head trauma injury is selected from the group consisting of blunt trauma, closed head injury and penetrating trauma injury.
9. The method according to claim 8, wherein said head trauma injury is closed head injury.
10. The method according to claim 6, wherein said injury, disease, disorder or condition is brain damage caused by a cardiovascular event.
11. The method according to claim 10, wherein said cardiovascular event is cardiac arrest or cardiac surgery.
12. The method according to claim 6, wherein said injury, disease, disorder or condition is a cerebrovascular disorder or disease.
13. The method according to claim 12, wherein said cerebrovascular disorder is brain ischemia or stroke.
14. The method according to claim 6, wherein said injury, disease, disorder or condition is a neurodegenerative disease or disorder.
15. The method according to claim 14, wherein said neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis and macular degeneration.
16. The method according to claim 6, wherein said injury, disease, disorder or condition is dementia.
17. The method according to claim 16, wherein said dementia is Alzheimer's disease or a non-Alzheimer's dementia selected from the group consisting of senile dementia, Lewy body dementia, vascular dementia and a dementia caused by Parkinson's disease, Huntington's chorea, Creutzfeld-Jacob disease or HIV infection.
18. A method for conferring neuroprotection to an individual afflicted with a neurological injury, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological injury.
19. The method according to claim 18, wherein said neurological injury is selected from the group consisting of head trauma injury and spinal cord injury.
20. A method for conferring neuroprotection to an individual suffering from a neurological or neurodegenerative disease or disorder, which comprises administering to said individual a compound of formula I in claim 1 or an enantiomer or a pharmaceutically acceptable salt thereof in an amount effective to ameliorate the neurodegeneration associated with said neurological or neurodegenerative disease or disorder.
21. The method according to claim 20, wherein said neurological or neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, facial nerve (Bell's) palsy, multiple sclerosis, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, macular degeneration and dementia.